

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	SiteMinder Limited
<b>ABN</b>	59 121 931 744

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Sankar Narayan
<b>Date of last notice</b>	10 January 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct/Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Aquila Investment Management Pty Ltd as trustee for the Narayan Family Trust (a discretionary family trust which Sankar controls and is a beneficiary of)  Solium Nominees (AUS) Pty Ltd as trustee for SiteMinder Limited
<b>Date of change</b>	22 November 2023

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y  
Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p><u>Direct</u></p> <ol style="list-style-type: none"> <li>1. 7,095,320 fully paid ordinary shares</li> <li>2. 80,000 options granted under the 2017 Option Plan (each with an exercise price of \$3.45 and an expiry date of 1 July 2030)</li> </ol> <p><u>Indirect</u></p> <ol style="list-style-type: none"> <li>3. 52,371 fully paid ordinary shares</li> <li>4. 25,983 options granted under the LTIP (each with an exercise price of \$5.57 and an expiry date of 8 November 2025)</li> <li>5. 31,691 options granted under the LTIP (each with an exercise price of \$6.69 and an expiry date of 8 November 2025)</li> <li>6. 37,687 options granted under the LTIP (each with an exercise price of \$7.70 and an expiry date of 8 November 2025)</li> <li>7. 15,501 performance rights granted under the LTIP (1/3 vesting over 3 years from 8 November 2021)</li> <li>8. 328,680 Unlisted Options granted under the LTIP (each with an exercise price of \$3.84 and an expiry date being 90 days following the release of the Company's full year results for FY2027.</li> <li>9. 28,874 Performance Rights granted under the LTIP (vesting in two separate tranches with attaching performance conditions)</li> </ol>
<p><b>Class</b></p>	<ol style="list-style-type: none"> <li>1. Unlisted Options granted under the LTIP (each with an exercise price of \$4.53 and an expiry date being 90 days following the release of the Company's full year results for FY2028</li> <li>2. Performance Rights granted under the LTIP (subject to various vesting conditions with attaching performance conditions)</li> </ol>
<p><b>Number acquired</b></p>	<ol style="list-style-type: none"> <li>1. 356,129 Unlisted Options granted under the LTIP (each with an exercise price of \$4.53 and an expiry date being 90 days following the release of the Company's full year results for FY2028</li> <li>3. 48,952 Performance Rights granted under the LTIP (subject to various vesting conditions with attaching performance conditions)</li> </ol>
<p><b>Number disposed</b></p>	<p>N/A</p>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation</p>	<ol style="list-style-type: none"> <li>1. \$1.868 Per Option (The total number of Options granted has been calculated by dividing 150% of the MD and CEO's maximum FY2024 LTI Opportunity (which comes to a value of \$665,250), by the fair value of an Option following the release of the FY23 annual results (being \$1.868 per Option).</li> <li>2. \$4.53 Per Performance Right (The number of Performance Rights granted has been calculated by dividing 50% of the MD and CEO's maximum FY2024 LTI opportunity (which comes to a value of \$221,750), by the VWAP of the Company's ordinary Shares over the five trading days following the Company's annual results for FY23, being \$4.53.</li> </ol>
<p><b>No. of securities held after change</b></p>	<p><u>Direct</u></p> <ol style="list-style-type: none"> <li>1. 7,095,320 fully paid ordinary shares</li> <li>2. 80,000 options granted under the 2017 Option Plan (each with an exercise price of \$3.45 and an expiry date of 1 July 2030)</li> </ol> <p><u>Indirect</u></p> <ol style="list-style-type: none"> <li>3. 52,371 fully paid ordinary shares</li> <li>4. 25,983 options granted under the LTIP (each with an exercise price of \$5.57 and an expiry date of 8 November 2025)</li> <li>5. 31,691 options granted under the LTIP (each with an exercise price of \$6.69 and an expiry date of 8 November 2025)</li> <li>6. 37,687 options granted under the LTIP (each with an exercise price of \$7.70 and an expiry date of 8 November 2025)</li> <li>7. 15,501 performance rights granted under the LTIP (1/3 vesting over 3 years from 8 November 2021)</li> <li>8. 328,680 Unlisted Options granted under the LTIP (each with an exercise price of \$3.84 and an expiry date being 90 days following the release of the Company's full year results for FY2027.</li> <li>9. 28,874 Performance Rights granted under the LTIP (vesting in two separate tranches with attaching performance conditions)</li> <li>10. 356,129 Unlisted Options granted under the LTIP (each with an exercise price of \$4.53 and an expiry date being 90 days following the release of the Company's full year results for FY2028)</li> <li>11. 48,952 Performance Rights granted under the LTIP (subject to various vesting conditions with attaching performance conditions)</li> </ol>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Unlisted Options and Performance Rights issued under the terms of the SiteMinder Employee Equity Incentive Plan as approved at the 2023 Annual General Meeting.</p>

+ See chapter 19 for defined terms.

For personal use only

## Appendix 3Y Change of Director's Interest Notice

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only